Anti-RSV-F / Fusion Glycoprotein antibody

Cat.#: 100176

Special Price 290.3 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-RSV-F / Fusion Glycoprotein antibody
  • Documents
  • Description
    Rabbit monoclonal to RSV-F / Fusion Glycoprotein
  • Tested applications
    MN
  • Species reactivity
    Human respiratory syncytial virus (RSV) Fusion glycoprotein / RSV-F
    Has cross-reactivity with recombinant F protein of A type of long strain, A2 strain (502814), RSS2 strain (502155) and B type of B1 strain in ELISA assay
  • Alternative names
    Respiratory syncytial virus antibody; F antibody; Fusion protein (F) antibody; Protein F antibody; RSVgp08 antibody
  • Immunogen
  • Isotype
    Rabbit IgG
  • Preparation
    This antibody was obtained from a rabbit immunized with purified, recombinant Human respiratory syncytial virus (RSV) Fusion glycoprotein / RSV-F (AAB59858.1; Met1-Thr529) and was produced using recombinant antibody technology.
  • Clonality
    Monoclonal
  • Formulation
    0.2 μm filtered solution in PBS
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications
    Microneutralizaiton (MN) - The RSV F protein Neutralizing Antibody can effectively neutralize Human RSV A type A2 strain virus from infecting the Vero cells.
  • Validations

    Human respiratory syncytial virus (RSV) Fusion glycoprotein / RSV-F Neutralizing Antibody

    Human respiratory syncytial virus (RSV) Fusion glycoprotein / RSV-F Neutralizing Antibody

    The neutralization activity of RSV F protein antibody is Measured by Microneutralization test in vitro. The infection of VERO cells induced by 140-160 pfu of RSV A-A2 strain is neutralized by increasing concentrations of anti RSV Monoclonal Antibody (Catalog: 11049-R338). The neutralizing titer (IC50) of antibody is 0.6-2.3 µg/mL.
    Negative Control: VERO cells cells were infected with 140-160 pfu of RSV A-A2 strain;
    Positive Control: The RSV (140-160 pfu A-A2 strain) infection in VERO cells was inhibited by serial dilutions of positive Neutralizing Antibody;
    RSV-F R338: The RSV (140-160 pfu A-A2 strain) infection in VERO cells was inhibited by serial dilutions of RSV-F R338.
    Plaque numbers represent number of Plaque-forming units with or without antibody.

  • Background
    Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. It is classified within the genus pneumovirus of the family paramyxoviridae. Like other members of the family, HRSV has two major surface glycoproteins (G and F) that play important roles in the initial stages of the infectious cycle. The G protein mediates attachment of the virus to cell surface receptors, while the F protein promotes fusion of the viral and cellular membranes, allowing entry of the virus ribonucleoprotein into the cell cytoplasm. The fusion (F) protein of RSV is synthesized as a nonfusogenic precursor protein (F0), which during its migration to the cell surface is activated by cleavage into the disulfide-linked F1 and F2 subunits. This fusion is pH independent and occurs directly at the outer cell membrane, and the F2 subunit was identifed as the major determinant of RSV host cell specificity. The trimer of F1-F2 interacts with glycoprotein G at the virion surface. Upon binding of G to heparan sulfate, the hydrophobic fusion peptide is unmasked and induces the fusion between host cell and virion membranes. Notably, RSV fusion protein is unique in that it is able to interact directly with heparan sulfate and therefore is sufficient for virus infection. Furthermore, the fusion protein is also able to trigger p53-dependent apoptosis.
  • References
    • Martin-Gallardo A. et al., 1993, J Gen Virol. 74 (3): 453-8.
    • Jose A M. et al., 1997, J Gen Virol. 78: 2411-8.
    • Feldman SA. et al., 1999, J Virol. 73 (8): 6610-7.
    • Zlateva K.T. et al., 2004, J Virol. 78 (9): 4675-83.
    • Trento A. et al., 2006, J Virol. 80 (2): 975-84.
    • Branigan P J. et al., 2006, J Gen Virol. 87 (2): 395-8.
    • Eckardt-Michel J. et al., 2008, J. Virol. 82: 3236-49.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"